Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Autor: A. Sánchez, L. R. Brun, H. Salerni, P. R. Costanzo, D. González, A. Bagur, B. Oliveri, M. B. Zanchetta, V. Farías, L. Maffei, V. Premrou, J. L. Mansur, M. S. Larroudé, M. A. Sarli, P. Rey, M. R. Ulla, M. M. Pavlove, S. Karlsbrum, M. L. Brance
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Zdroj: Journal of Osteoporosis, Vol 2016 (2016)
Druh dokumentu: article
ISSN: 2090-8059
2042-0064
DOI: 10.1155/2016/8738959
Popis: The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Databáze: Directory of Open Access Journals